Blanchet Martine, Ducharme Anique, Racine Normand, Rouleau Jean Lucien, Tardif Jean Claude, Juneau Martin, Marquis Johanne, Larivée Lucie, Nigam Anil, Fortier Anick, White Michel
Research Center, Montreal Heart Institute, Quebec, Canada.
Am J Cardiol. 2003 Sep 1;92(5):548-53. doi: 10.1016/s0002-9149(03)00723-9.
Patients with congestive heart failure (CHF) exhibit a decrease in maximal exercise capacity in response to a cold environment. The aim of this study was to further investigate the impact of cold exposure on submaximal exercise capacity, systemic adrenergic drive, and the effects of long-term beta-adrenergic blockade on these parameters. Thirty-three patients with CHF, with exercise limited by dyspnea and left ventricular ejection fraction of 26 +/- 4%, were randomized to receive metoprolol or carvedilol for 6 months. The observations were compared with 12 age-matched healthy volunteers. Maximal exercise performance with gas exchange analyses were assessed using a ramp protocol, and endurance capacity was measured using 2 constant-load exercise tests performed randomly at 20 degrees C and -8 degrees C. Healthy volunteers increased their submaximal exercise time by 20% (1,353 +/- 455 [20 degrees C] vs 1,635 +/- 475 seconds [-8 degrees C]; p <0.05), whereas patients with CHF exhibited a 21% decrease in exercise time (1,182 +/- 549 [20 degrees C] vs 931 +/- 524 seconds [-8 degrees C]; p <0.05) at -8 degrees C. Beta blockers increased submaximal exercise duration at 20 degrees C (+261 +/- 617 seconds; p <0.05) and -8 degrees C (+374 +/- 729 seconds; p <0.05). Norepinephrine increased to a greater extent at 4 minutes and at the time of exhaustion (at -8 degrees C) only in patients with CHF. Beta-adrenergic blockade caused no significant decrease in plasma norepinephrine levels. Patients with symptomatic CHF exhibited a significant decrease in submaximal exercise time in response to moderate cold exposure. Beta-blocker therapy with either metoprolol or carvedilol significantly increases submaximal exercise time and attenuates the impact of cold exposure on functional capacity.
充血性心力衰竭(CHF)患者在寒冷环境下最大运动能力会下降。本研究的目的是进一步调查冷暴露对次最大运动能力、全身肾上腺素能驱动的影响,以及长期β-肾上腺素能阻滞剂对这些参数的作用。33例CHF患者,运动因呼吸困难受限,左心室射血分数为26±4%,被随机分为接受美托洛尔或卡维地洛治疗6个月。将观察结果与12名年龄匹配的健康志愿者进行比较。使用斜坡方案通过气体交换分析评估最大运动表现,并通过在20℃和-8℃随机进行的2次恒定负荷运动测试测量耐力。健康志愿者的次最大运动时间增加了20%(1353±455秒[20℃]对1635±475秒[-8℃];p<0.05),而CHF患者在-8℃时运动时间减少了21%(1182±549秒[20℃]对931±524秒[-8℃];p<0.05)。β受体阻滞剂在20℃(增加261±617秒;p<0.05)和-8℃(增加374±729秒;p<0.05)时增加了次最大运动持续时间。仅在CHF患者中,去甲肾上腺素在4分钟时以及力竭时(在-8℃)升高幅度更大。β-肾上腺素能阻滞剂未导致血浆去甲肾上腺素水平显著降低。有症状的CHF患者在中度冷暴露后次最大运动时间显著减少。美托洛尔或卡维地洛的β受体阻滞剂治疗显著增加了次最大运动时间,并减轻了冷暴露对功能能力的影响。